Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
18.54
-0.73 (-3.79%)
At close: Jun 17, 2025, 4:00 PM
17.80
-0.74 (-3.99%)
After-hours: Jun 17, 2025, 7:14 PM EDT
Castle Biosciences Revenue
Castle Biosciences had revenue of $87.99M in the quarter ending March 31, 2025, with 20.57% growth. This brings the company's revenue in the last twelve months to $347.08M, up 38.43% year-over-year. In the year 2024, Castle Biosciences had annual revenue of $332.07M with 51.09% growth.
Revenue (ttm)
$347.08M
Revenue Growth
+38.43%
P/S Ratio
1.50
Revenue / Employee
$456,088
Employees
761
Market Cap
535.29M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CSTL News
- 1 day ago - Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - GlobeNewsWire
- 6 days ago - Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - GlobeNewsWire
- 13 days ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - GlobeNewsWire
- 19 days ago - New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes - GlobeNewsWire
- 27 days ago - Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result - GlobeNewsWire
- 5 weeks ago - Castle Biosciences Celebrates Skin Cancer Awareness Month - GlobeNewsWire
- 6 weeks ago - Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript - Seeking Alpha